Cargando…
Pyrotinib Sensitizes 5-Fluorouracil-Resistant HER2(+) Breast Cancer Cells to 5-Fluorouracil
5-Fluorouracil (5-FU) is a widely used chemotherapeutic agent for breast cancer. However, acquired chemoresistance leads to a loss of its efficacy; methods to reverse are urgently needed. Some studies have shown that pyrotinib, an ErbB receptor tyrosine kinase inhibitor, is effective against HER2(+)...
Autores principales: | Yi, Jianing, Chen, Shuai, Yi, Pingyong, Luo, Jinlin, Fang, Meng, Du, Yang, Zou, Lianhong, Fan, Peizhi |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Cognizant Communication Corporation
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7751227/ https://www.ncbi.nlm.nih.gov/pubmed/32727638 http://dx.doi.org/10.3727/096504020X15960154585410 |
Ejemplares similares
-
53BP1 Sensitizes Breast Cancer Cells to 5-Fluorouracil
por: Li, Xiaoyan, et al.
Publicado: (2013) -
Effects of the Plasma Concentration of 5‐Fluorouracil and the Duration of Continuous Venous Infusion of 5‐Fluorouracil with an Inhibitor of 5‐Fluorouracil Degradation on Yoshida Sarcomas in Rats
por: Fujii, Setsuro, et al.
Publicado: (1989) -
Continuous 5-fluorouracil in the treatment of breast cancer.
por: Cameron, D. A., et al.
Publicado: (1994) -
Docetaxel, cisplatin, and 5-fluorouracil compared with epirubicin, cisplatin, and 5-fluorouracil regimen for advanced gastric cancer: A systematic review and meta-analysis
por: Li, Bo, et al.
Publicado: (2019) -
Hyperammonemia Secondary to 5-Fluorouracil
por: Scott, Ashley, et al.
Publicado: (2023)